Goodsurance

Drug prices & Part D

Medicare Part D Has No Announced Successor for GLP-1 Coverage Once the Bridge Program Closes at End of 2027

CMS paused the BALANCE Model for Medicare drug plans indefinitely in April 2026 after insurers did not sign up in sufficient numbers, leaving the 50-dollar-copay bridge as the only Part D GLP-1 pathway, now extended through December 2027.

By the Goodsurance editorial teamJuly 18, 2026

When CMS launched the Medicare GLP-1 Bridge on July 1, 2026, the program was designed as a six-month transition to a permanent model called BALANCE. In April 2026, CMS announced it was delaying the BALANCE Model for Medicare Part D indefinitely after plan sponsors representing less than the required 80 percent of Part D enrollment applied to participate. Insurers cited uncertainty about Part D market conditions and insufficient time to build actuarial models around GLP-1 utilization.

To preserve access, CMS extended the bridge from six months to 18 months, running through December 31, 2027. Under the bridge, eligible Part D enrollees with obesity or overweight and at least one related condition, such as high blood pressure or Type 2 diabetes, can access qualifying GLP-1 medications for a flat copay, provided they meet clinical criteria and are not already using a GLP-1 for a separately covered indication.

CMS has not announced a replacement model for Medicare Part D after December 2027. The Medicaid component of BALANCE is moving forward separately: state Medicaid agencies could apply to join through July 31, 2026, and eligible Medicaid enrollees in participating states gain access as early as May 2026.

Medicare Rights Center has noted the uncertainty this creates for beneficiaries who start GLP-1 therapy under the bridge and may face a coverage gap after 2027 if no follow-on model is announced. CMS has said it will use data gathered during the bridge to inform future Part D planning.

In plain words

Medicare started covering GLP-1 weight-loss drugs for qualifying members on July 1, 2026. People pay a flat copay. This access runs through December 2027. A bigger permanent program was supposed to take over, but not enough insurance companies signed up, so it was put on hold with no date set. Right now there is no plan for what happens after the bridge ends in late 2027. A related program for Medicaid, the low-income health program, is still going forward in some states.

Understand the basics first

Source: CMS Innovation Center
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

KFF: Medicare Advantage Drug Plans Received Over 600 Dollars Per Member in Rebates That Standalone Drug Plans Cannot Access

A KFF analysis explains the structural payment asymmetry that makes it harder for standalone Part D plans to compete on drug premiums, as the number of those plans hits record lows ahead of open enrollment.

August 8, 2026

Drug prices & Part D

Bipartisan Senate Bill Would Preserve Drug Discounts for Safety-Net Hospitals and Shut Down a Rebate Pilot

Six senators from both parties introduced the SUSTAIN 340B Act on August 5, proposing to protect point-of-purchase drug discounts for safety-net providers while adding new transparency and audit requirements.

August 6, 2026

Drug prices & Part D

CMS Counted a 2020 Reclassification Date for Creon, Delaying Medicare Price Talks by Years, Report Says

Public Citizen says CMS allowed AbbVie to use the date Creon was reclassified as a biologic rather than its original FDA approval date, pushing the drug's eligibility for Medicare price negotiation years into the future.

August 5, 2026

Drug prices & Part D

Medicare Part D Deductible Rises to 700 Dollars and Out-of-Pocket Drug Cap Reaches 2,400 Dollars for 2027

The Inflation Reduction Act tied the Medicare Part D annual deductible and catastrophic spending limit to drug cost growth, and both parameters rise again for 2027, continuing an upward pattern as specialty and GLP-1 drug spending climbs across the program.

August 4, 2026

Drug prices & Part D

Medicare and Drug Manufacturers Are Holding Negotiation Meetings This Summer on 15 High-Cost Drugs, With Final Prices Due by November

The third cycle of Medicare drug price negotiations is in its most active phase, with CMS and participating manufacturers in sessions that must conclude by November 1, 2026, to set maximum fair prices on cancer, HIV, and other specialty drugs taking effect in 2028.

August 3, 2026

Drug prices & Part D

CMS Confirms the 2027 Medicare Part D Base Premium at 41 Dollars and 33 Cents as a Federal Stabilization Subsidy for Drug Plans Ends

The confirmed base premium equals the maximum 6 percent annual increase the Inflation Reduction Act allows, but consumer advocates warn that actual plan-level premiums, which are set above that floor, are likely to climb sharply once a temporary federal subsidy expires at year-end.

July 30, 2026